Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the stock.

Trinity Biotech Stock Performance

Shares of Trinity Biotech stock opened at $1.85 on Wednesday. Trinity Biotech has a one year low of $1.79 and a one year high of $5.50. The business has a 50-day simple moving average of $2.06 and a 200-day simple moving average of $2.25. The company has a market cap of $14.10 million, a PE ratio of -0.58 and a beta of 1.21.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings data on Wednesday, January 31st. The company reported ($0.90) earnings per share for the quarter. The business had revenue of $14.68 million during the quarter. On average, sell-side analysts predict that Trinity Biotech will post -1.5 earnings per share for the current fiscal year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.